糖尿病口服降糖药新进展.pptVIP

没有最好，只有更适合！ * * Sulfonylureas and meglitinides are insulin secretagogues. They stimulate insulin release from beta cells. Patients with type 1 diabetes or later stages of type 2 diabetes, who lack a sufficient number of functional beta cells, do not respond to these medications. [Fowler2007b, 132C; AmarylPI, 2B; StarlixPI, 1D] References: [Fowler2007] Fowler MJ. Diabetes treatment, part 2: oral agents for glycemic management. Clin Diabetes. 2007;25(4):131-134. [AmarylPI] Amaryl? (glimepiride tablets) prescribing information. Bridgewater, NJ: sanofi-aventis US; February, 2006. [StarlixPI] Starlix? (nateglinide) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; November, 2006. * * The second-generation sulfonylureas, glyburide, glimepiride, and glipizide, have better safety profiles than older first-generation agents such as tolbutamide. [Fowler2007b, 132C] Although potencies vary among different products, sulfonylureas typically reduce A1C by 1.5% to 2.0%. They reduce fasting plasma glucose (FPG) and postprandial glucose (PPG). [Fowler2007b, 132C; GlucotrolXLPI, 4C; AmarylPI, 2AB] Standard and extended-release formulations of sulfonylureas are typically taken once daily, either with, or immediately prior to, breakfast or the first meal of the day. [GlucotrolPI, 8DE; GlucotrolXLPI, 11C, 12E; AmarylPI, 15D; MicronasePI, 5K] References: [Fowler2007] Fowler MJ. Diabetes treatment, part 2: oral agents for glycemic management. Clin Diabetes. 2007;25(4):131-134. [GlucotrolXL2006] Glucotrol? XL (glipizide) extended release tablets prescribing information. New York, NY: Pfizer, Inc.; September, 2006. [AmarylPI2006] Amaryl? (glimepiride tablets) prescribing information. Bridgewater, NJ: sanofi-aventis US; February, 2006. [GlucotrolPI] Glucotrol? (glipizide) tablets prescribing information. New York, NY: Pfizer, Inc.; September, 2006. [MicronasePI] Micronase? (glyburide tablets, USP). Kalamazoo, MI: Pharmacia Upjohn Com